A Cohort Study of Metformin Exposure and Survival in Patients with Stage I–III Colorectal Cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Preclinical evidence suggests a beneficial effect of metformin in colorectal cancer. This study aimed to investigate associations between metformin exposure and colorectal cancer–specific survival using population-level data. Methods: Adult patients with stage I–III colorectal cancer diagnosed from 2001 to 2006 were identified from the National Cancer Registry Ireland. Use of metformin and other antidiabetic medications was determined from a linked national prescription claims database. Multivariate Cox regression was used to estimate hazard ratios (HR) with 95% confidence intervals (CI) for associations between prediagnostic metformin exposure (versus nonmetformin antidiabetic drugs) and colorectal cancer–specific mortality. Models were stratified by antidiabetic drug coprescription and intensity of metformin exposure. Results: The cohort included 207 diabetics who received metformin, 108 diabetics not exposed to metformin, and 3,501 nondiabetic patients. In multivariate analyses, a nonsignificant reduction in colorectal cancer–specific mortality was observed for metformin-exposed patients relative to other treated diabetics (HR, 0.61; 95% CI, 0.37–1.01). In stratified analyses, no significant association was observed for patients receiving low-intensity metformin or metformin in combination with other antidiabetic drugs. High-intensity exclusive metformin use was associated with a significant reduction in colorectal cancer–specific mortality (HR, 0.44; 95% CI, 0.20–0.95). Conclusions: Significant associations between metformin exposure and colorectal cancer–specific mortality were observed only for high-intensity exclusive metformin use in the diabetic cohort. Impact: This study provides moderate evidence of an association between metformin exposure and improved colorectal cancer survival in a diabetic population. Additional studies in larger cohorts, with detailed information on diabetes severity, are required to confirm these results. Cancer Epidemiol Biomarkers Prev; 22(8); 1364–73. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Simulation Study of Confounder-Selection Strategies
Maldonado, G., & Greenland, S. (1993) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116813 · Cited by 2,491 · cited 1×
“The final multivariate model was selected using backward elimination on the basis of a maximum cumulative change in the risk estimates of 10% (31, 32).”
MethodMetformin suppresses intestinal polyp growth in Apc Min/+ mice
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00933.x · Cited by 185
On model selection and model misspecification in causal inference.
Vansteelandt, S., Bekaert, M., & Claeskens, G. (2012) · Statistical Methods in Medical Research · doi:10.1177/0962280210387717 · Cited by 172 · cited 1×
“The final multivariate model was selected using backward elimination on the basis of a maximum cumulative change in the risk estimates of 10% (31, 32).”
Method
Cited by
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis
Coyle, C., Cafferty, F. H., Vale, C., & Langley, R. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw410 · Cited by 452
Saraei, P., Asadi, I., Kakar, M. A., & Moradi-Kor, N. (2019) · Cancer Management and Research · doi:10.2147/cmar.s200059 · Cited by 350
Yin, M., Zhou, J., Gorak, E. J., & Quddus, F. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0111 · Cited by 157
Nair, V., Sreevalsan, S., Basha, R., Abdelrahim, M., Abudayyeh, A., Rodrigues Hoffman, A., & Safe, S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.592576 · Cited by 129
Yamaguchi, N., Weinberg, E. M., Nguyen, A., Liberti, M. V., Goodarzi, H., Janjigian, Y. Y., Paty, P. B., Saltz, L. B., Kingham, T. P., Loo, J. M., et al. (2019) · eLife · doi:10.7554/elife.52135 · Cited by 91
Metadata
- Authors
- Spillane, S., Bennett, K., Sharp, L., & Barron, T. I.
- Venue
- Cancer Epidemiology, Biomarkers & Prevention
- Published
- 2013-07-31
- Volume
- 22
- Issue
- 8
- Pages
- 1364-1373
- ISSN
- 1055-9965 (ISSN-L)
- 1538-7755
- OpenAlex
- W2098725808
- Cited by
- 91
- References
- 3
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Cohort Study of Metformin Exposure and Survival in Patients with Stage I–III Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1055-9965.epi-13-0347
- The paper
- Spillane, S., Bennett, K., Sharp, L., & Barron, T. I. (2013). A Cohort Study of Metformin Exposure and Survival in Patients with Stage I–III Colorectal Cancer. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-13-0347
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.